FIELD: biochemistry.
SUBSTANCE: invention relates to the field of biochemistry, in particular to an anti-LAG-3 antibody or its antigen-binding part, which specifically binds to LAG-3, a method for its production, as well as a composition containing it. A selected nucleic acid molecule encoding chains of the above-mentioned antibody, as well as a cell containing the above-mentioned nucleic acid are also disclosed. The invention also relates to a method for strengthening immunity in a patient providing for the use of the above-mentioned antibody or its part.
EFFECT: invention provides for the effective treatment of a patient with a LAG-3-related disorder.
25 cl, 9 dwg, 10 tbl, 14 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HIGH-AFFINITY ANTI-PD-1 AND ANTI-LAG-3 ANTIBODIES AND BISPECIFIC BINDING PROTEINS OBTAINED FROM THEM | 2019 |
|
RU2782381C2 |
| BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO PD1 AND LAG3 | 2018 |
|
RU2778805C2 |
| BINDING MOLECULES, BINDING PD-L1 AND LAG-3 | 2017 |
|
RU2784388C2 |
| POLYSPECIFIC POLYPEPTIDE CONSTRUCTS WITH LIMITED BINDING TO CD3 AND METHODS OF THEIR APPLICATION | 2018 |
|
RU2813816C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODY TO LAG-3 AND ITS USE | 2018 |
|
RU2771384C2 |
| ANTIBODY AGAINST LAG-3 | 2017 |
|
RU2744866C2 |
| ANTIBODIES DIRECTED TO PROTEIN OF PROGRAMMED DEATH OF CELL-1 (PD-1) | 2014 |
|
RU2723050C2 |
| ANTIBODY FOR TREATMENT OF AUTOIMMUNE DISEASES | 2017 |
|
RU2781148C2 |
| COMBINED MEDICINAL PRODUCTS TARGETING PD-1, TIM-3 AND LAG-3 | 2018 |
|
RU2795232C2 |
| ANTI-PD-L1 AND IL-2 CYTOKINES | 2017 |
|
RU2769282C2 |
